Shared on 23 Oct 25
Fair value Increased 2.36%Analyst Commentary Highlights Resilience and Upgraded Valuation Outlook for IQVIA Holdings
The analyst price target for IQVIA Holdings has increased by approximately $5 to $223, as analysts cite the company's business resilience, workforce stability, and diversified client base as key drivers for higher valuation. Analyst Commentary Recent analyst updates highlight a mix of confidence and caution regarding IQVIA Holdings' future outlook, referencing the company's performance, client diversification, and sector positioning.
Shared on 08 Oct 25
Fair value Increased 1.10%NVIDIA Partnership And AI Analytics Will Reshape Life Sciences
Analysts have slightly increased their price target for IQVIA Holdings from approximately $215.89 to $218.26. They cite improved demand momentum, strong segment performance, and business resilience relative to peers as reasons for the adjustment.
Shared on 11 Sep 25
Fair value Increased 0.74%NVIDIA Partnership And AI Analytics Will Reshape Life Sciences
Analysts have modestly raised IQVIA’s price target to $215.89, citing strong B2B metrics, business diversification, and resilience in core segments despite sector headwinds and macroeconomic uncertainty. Analyst Commentary Bullish analysts cite IQVIA’s stronger business-to-business metrics, workforce stability, and lower customer concentration as reasons for outperformance and insulation against pharma sector restructurings, supporting higher valuation multiples.
Shared on 07 May 25
Fair value Decreased 6.60%NVIDIA Partnership And AI Analytics Will Reshape Life Sciences
Shared on 30 Apr 25
Fair value Increased 1.26%FDA Reforms And NVIDIA Collaboration Will Lower Operating Costs
AnalystConsensusTarget has decreased shares outstanding growth rate from -0.0% to -0.0%.
Shared on 23 Apr 25
Fair value Decreased 0.85%FDA Reforms And NVIDIA Collaboration Will Lower Operating Costs
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 16 Apr 25
Fair value Decreased 7.97%FDA Reforms And NVIDIA Collaboration Will Lower Operating Costs
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Decreased 1.28%FDA Reforms And NVIDIA Collaboration Will Lower Operating Costs
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 1.96%FDA Reforms And NVIDIA Collaboration Will Lower Operating Costs
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
FDA Reforms And NVIDIA Collaboration Will Lower Operating Costs
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Increased 29%FDA Reforms And NVIDIA Collaboration Will Lower Operating Costs
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 10 Mar 25
Fair value Decreased 34%